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Clinical Manifestations

Introduction

§
Dyspnea
§
Persistent cough
§
Frothy or pink sputum
§
Edema
§
Jugular vein distention
§
Low urine output
§
Pulmonary edema
§
 or ¯ BP
§
Potential S3 gallop on auscultation of heart
(McCance & Huether, 2018)

Heart failure with reduced ejection fraction (HFrEF) is:
A chronic disease
On the rise among the population (will  by 46% in the next 10
years)(Bowers, 2019)
Costs upwards of $70 billion annually (Murphy et al., 2019)
HFrEF leads to high morbidity and mortality as well as repeat
hospitalizations for exacerbation of symptoms (Rhiantong et al.,
2019). HFrEF is the focus of this poster, however, HF with preserved
EF (HFpEF) will be mentioned to compare and contrast the severity
of HFrEF. Differences in HFrEF and HFpEF lie in the
pathophysiology, treatment, and outcomes. HFrEF is a disease that is
complicated with treatment focused on keeping symptoms
mitigated. However, there is constant developing research in
understanding the pathophysiology and treatments for this and
other types of HF affecting people around the world (Ge et al., 2019).

Pathophysiology

Cardiac cell dysfunction
¯
Renin-angiotensin aldosterone system (RAAS)  preload
¯
Ventricular remodeling due to over activation of RAAS
(Wan et al., 2019)

Stages of HF

HF is staged on a four-level progression of symptom and disease
state. This A-D range developed by The American College of
Cardiology and the American Heart Association defines the
different stages of HF. The stage at which a person is in their HF
disease progression dictates the type of intervention (Capriotti &
Micari, 2019) This progression scale is often used in conjunction
with the New York Heart Association classification of HF.

Remodeling & Cellular Changes

Disease Focused Diagnostics
Noninvasive
§

§
§
§
§

Thorough history and physical ® valuable information based on
discussion of history, symptoms, comorbidities, and physical
assessment
Serum blood levels ® elevated BNP correlates with HF
12-lead ECG ® determine if there is ventricular hypertrophy
Chest x-ray (PA/LAT) ® visualize heart and lungs
Transthoracic echocardiogram ® heart size and
functionality/determines EF

Invasive

Coronary angiogram ® excludes coronary disease as a cause/assess
severity of pulmonary HTN
Hemodynamic monitoring *heart pressures and pulmonary capillary
wedge (PCW) pressures ® if elevated, proceed to drug studies
§
Drug studies utilizing pulmonary v. systemic vasodilators ® assess
which medication is effective in improving cardiac output *last resort
testing method*
(Wan et al., 2019)
§
§

Mechanism of pharmacotherapies

Change in the formation of the heart
Response to an insult to the myocardium
Hemodynamic overload
Poor prognosis if maladaptive *adaptive remodeling is in response to
normal changes*
§
Cardiac muscle cells decrease in amount and enlarge in size®maintain
stroke volume®ventricular wall thickens
§
Activation of RAAS quickens the remodeling process
§
Increase of proinflammatory cytokines
(Colucci, 2018)
§
§
§
§

Treatment
Pharmacotherapies

Angiotensin-converting enzyme (ACE) inhibitor
§
Lisinopril/Enalapril
Angiotensin II receptor blocker (ARB) *if ACE is ineffective*
§
Valsartan/Candesartan
Angiotensin receptor neprilysin inhibitor (ARNI) *must stop ACE
before initiating*
§
Sacubitril/Valsartan (Entrestoä)
b-Blocker *appropriate if no hypotension and HR>50*
§
Carvedilol/Metoprolol
Mineralocorticoid receptor antagonist (MRA) *used in
conjunction with Entrestoä*
§
Spironolactone/Eplerenone
Loop diuretic *assists with excess fluid removal/will cause a
decrease in K+ levels*
§
Furosemide
Hyperpolarization-activated cyclic nucleotide-gated channel
blocker *appropriate if NSR, tolerating all other medications at
max level*
§
Ivabradine
Cardiac glycoside
§
Digitalis
Direct-acting vasodilator *stable/African-American*
§
Hydralazine/Isosorbide
Evidence-based pharmacologic treatment for HFrEF displaying a
decrease in hospitalizations and improvement in QoL (Albert &
Kozinn, 2018, p. 18).

Left Ventricular Assistive Device (LVAD)
End-stage HF
Two indications: bridge to transplant (BTT) or destination
therapy (DT)
§
Takes over the function of the heart muscle and maintains
cardiac output
§
Risk of complications: infection, blood clots, GI bleed,
dysrhythmias, stroke
(Capriotti & Micari, 2019)
§
§

(El Hussein et al., 2020)

Remodeling and Treatment?
HF treatment aims to slow the process of remodeling and reduce
the activation of RAAS. The goal is to cease the advancement of
the disease (Bowers, 2019). HFrEF and HFpEF may exist
concurrently, however, treatment methods vary (Murphy et al.,
2019)

Implications for the Advanced Practice Nurse
§
§
§
(Chavey et al., 2017, Table 1)

(Solimando, 2017)

§
§
§

Assess and intervene on modifiable variables r/t medication regimens starting with inpatient initiation of pharmacological
interventions ®cost, knowledge deficit/depression/mental health (Albert & Kozinn, 2018)
Lead HF clinics utilizing a multidisciplinary approach ®patients will reach optimization in pharmacological therapies and remain
adherent
Evaluate need for implantable cardiac defibrillator (ICD) placement ®placement post-cardiac injury with a rEF reduces mortality
(Chan et al., 2020)
Telehealth visits ®assess symptoms to avoid rapid decompensation
Evaluate need for invasive/noninvasive monitoring devices ® assess impeding decompensation (Murphy et al., 2019)
LVAD-education on expectations/risks and complications/effects on QoL/palliative care (Kaiser, 2019)
*LAST TREATMENT OPTION FOR HFrEF/NOT ELIGIBLE FOR TRANSPLANT*

Conclusion
HFrEF is a chronic disease in which
treatment is constantly evolving.
The pathophysiology of the disease
and ways to effectively manage
HFrEF are everchanging. Hence,
research continues on the molecular
changes that occur within the heart
as well as appropriate therapies for
disease management. The APN is in
a front-line role to educate patients
and initiate therapies to prevent
readmissions. APN led HF clinics are
beneficial in ensuring faster followup after discharge. Knowledge
sharing between the APN and
patient can increase the patient with
HFrEF adherence and quality of life.
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